17 results about "Aqueous buffer" patented technology

An embolic hydrogel for a patient comprises an aqueous buffer and at least one functionalized polymer, each having at least one polymer backbone chemically modified with one or more functional groups. The functional groups facilitate the formation of a primary reversible cross-link on the polymer backbone such that the embolic hydrogel transitions from a gel state to a viscous liquid state in response to shear forces applied to the embolic hydrogel and transitions from the viscous liquid state to the gel state in response to the absence of shear forces applied to the embolic hydrogel. The embolic hydrogel also includes at least one phase change polymer that produces secondary crosslinking therein in response to a physiological environment such that the embolic hydrogel transitions from a gel state to a solid state.

A rapid, field-deployable method and associated kit for the qualitative detection of zinc fortification in wheat flour are disclosed. ፐከ6 method includes treating a wheat flour sample suspected of containing added zinc with a chromogenic reagent comprising dithizone dissolved in an ethanol solvent to induce a visually discernible color change from a blue profile to a pink-purple or red profile. The assay can be performed 85 8 surface spot test or as ል testtube liquid assay, the latter utilizing an aqueous buffer solution maintained at a pH of 5.5 to 6.0 to mobilize zinc ions. The resulting color change is evaluated against an intentionally fortified wheat flour standard. When validated against an Inductively Coupled Plasma Mass Spectrometry (ICP-MS) reference standard, the assay exhibits a sensitivity of 96.5%, a specificity of 90.9%, an overall misclassification rate of 5.88%, and 8 Cohen's kappa coefficient (k) of 0.88.

The invention provides a lipidosome adjuvant system based on furanose type QS-21 saponin molecules and a preparation method. The lipidosome adjuvant system comprises lipidosome and the QS-21 saponin molecules, the lipidosome comprises a lipid bilayer formed by ionizable lipid, structural phospholipid and cholesterol, the QS-21 saponin molecule is in a furanose type and is loaded on the lipidosome, and the QS-21 saponin molecule is partially inserted into the lipid bilayer through hydrophobic triterpenoid aglycone of the QS-21 saponin molecule. The preparation method comprises the following steps: dissolving lipidosome components forming lipid bilayers in an organic solvent to form a lipid phase, dissolving furanose type QS-21 saponin molecules in an acidic aqueous phase buffer solution to form a QS-21 aqueous phase, mixing the lipid phase and the QS-21 aqueous phase, precipitating lipid, and self-assembling to form lipidosome nanoparticles loaded with furanose type QS-21 saponin molecules, and finally, purifying to remove the organic solvent and the unencapsulated QS-21 molecules. According to the invention, through well-designed lipid composition and a preparation process, furanose type QS21 molecules are stably integrated into the lipidosome.

This invention discloses an N-substituted pyridine fluoroborate inner salt reagent, its preparation method, and its application in the preparation of F-18 radiopharmaceuticals. The N-substituted pyridine fluoroborate inner salt reagent is obtained by reacting protonated pyridine fluoroborate of Formula I with a compound of Formula II in the presence of a solvent. This inner salt reagent, through a substituted alkyl group linked to the pyridine N-phase, can undergo a coupling reaction with molecules containing specific groups (including drug molecules or their derivatives) to generate F-18 radiopharmaceutical precursors. Further isotope exchange reactions yield the F-18 radiopharmaceutical. By adjusting the types of substituents in the substituted alkyl group, this invention can achieve the construction of structurally diverse F-18 radiopharmaceutical precursors with different drug molecules or their derivatives. Furthermore, the prepared F-18 radiopharmaceutical precursors exhibit good stability in aqueous phase and can undergo efficient reactions in aqueous buffer solutions. 18 F- 19 The F isotope exchange reaction avoids the time-consuming dehydration process in the traditional F-18 radiopharmaceutical synthesis, greatly shortening the synthesis time and thus effectively improving the efficiency of F-18 radiopharmaceutical synthesis. 18 F-labeling rate.

The invention relates to the field of biotechnology, medicine and cosmetology, and more particularly to a hybrid matrix for use as a biological graft in the preparation of cardiac prostheses. The technical result of the invention includes improving the surface biocompatibility and the stability and durability of a biological graft which provides an antimicrobial response, and also preventing calcification. A method for producing a hybrid biomatrix comprises the following steps: pre-purifying a base of a biomatrix for 0.75-6 hours in two stages, consisting in the decellularization of xenopericardium in a 2-5 wt% water-alcohol solution of Tween-80, saturated with CO2, at a temperature of 20-400°C and a pressure of 10-30 MPa, and the subsequent decellularization of the xenopericardium in a multi-component system containing a solution based on supercritical CO2 and a 1-1.5 vol% addition of a 2-5 wt% water-alcohol solution of Tween-80, at a temperature of 20-400°C and a pressure of 10-30 MPa; stabilizing the biomatrix base by treatment with a 0.1-0.5 wt% aqueous buffer solution of genipin having a pH of 6.0-7.4 for 3-4 hours; and applying to the pre-purified biomatrix base a coating consisting of an aqueous solution of chitosan nanoparticles with an antimicrobial doping additive in the form of silver or vancomycin nanoparticles in a carbonic acid solution, at a pressure of 20-30 MPa and a temperature of 23-270°C for 1-6 hours.

An aqueous pharmaceutical solution for the treatment of a central nervous system (CNS) disorder is provided, the solution comprising at least 5 mg / ml dissolved levodopa and a pH in the range of 3.0 to 8.5. The solution is provided by mixing: a) an aqueous stock solution comprising levodopa, the stock solution having a pH of less than 2.8 at 25°C, and b) an aqueous buffer solution for increasing the pH of the stock solution, the buffer solution having a pH of at least 4.0 at 25°C. The aqueous pharmaceutical solution is administered to a subject having a central nervous system (CNS) disorder shortly after mixing the aqueous stock solution and the aqueous buffer solution. Further, a kit for administering an aqueous pharmaceutical solution to a subject having a central nervous system (CNS) disorder is provided.

A process for the preparation of a compound of formula (I) wherein R1 is selected from one or more of the following: alkyl, substituted alkyl, haloalkyl, cyanoalkyl, alkoxy, halogen, haloalkoxy, amino, aminoalkyl, alkylsulfonyl, arylsulfonyl, alkylsulfanyl and hydroxyl wherein n is selected from 1, 2 or 3, the process comprises reacting a compound of formula (II) with 2-haloheptafluoropropane in the presence of sodium dithionite (Na2S2O4) and an aqueous buffer, where the aqueous buffer comprises an acid and a base.

This invention discloses a hexavanadate-bridged double-ended click nucleic acid probe construct, its preparation method, and its application, relating to the field of bioanalytical technology. The hexavanadate-bridged double-ended click nucleic acid probe construct comprises a hexavanadate derivative V6-(N3)2 bridging scaffold with azido groups at both ends, and two identical oligonucleotides MB1 or MB2; MB1 is terminally alkyne and labeled with a FAM fluorescent group, and MB2 is terminally alkyne and labeled with a Cy5 fluorescent group; V6-(N3)2 and MB1 or MB2 undergo a Cu(I)-catalyzed azido-alkynyl cycloaddition reaction to form a 1,2,3-triazole linker bond, connecting to form an MB1-triazole-V6-triazole-MB1 or MB2-triazole-V6-triazole-MB2 structure. This invention also discloses a method for preparing this construct, wherein the finished product is obtained through a click reaction in an aqueous buffer system, copper removal and desalting, and separation and purification. And its application in nucleic acid sequence-specific detection, with its fluorescence quantitative readout mechanism, improves the robustness of sequence identification, mismatch detection and quantitative detection, and is suitable for pathogen identification, gene mutation screening, molecular diagnostics and drug companion diagnostics.

The invention discloses a preparation method and application of organic semiconductor lipid nanoparticles for near-infrared two-region imaging. The preparation method comprises the following steps: (a) dissolving an organic semiconductor molecule BTP-IC-OD, soybean lecithin SPC, cholesterol Chol and distearoyl phosphatidyl ethanolamine-polyethylene glycol-folic acid DSPE-PEG-FA in an organic solvent to form an organic phase; (b) carrying out reduced pressure rotary evaporation to remove the organic solvent to form a uniform composite film containing the components; (c) adding a water-phase buffer solution to hydrate the composite film to form a crude liposome suspension; and (d) extruding and granulating the crude liposome suspension through a filter membrane with the pore diameter of 80-200nm. The organic semiconductor lipid nanoparticles can clearly draw the boundary of a tumor focus and detect conventional small metastatic lymph nodes which are difficult to find, and a novel tool is provided for early diagnosis of malignant tumors, real-time navigation guide excision in an operation and curative effect monitoring.

Compositions, methods, and kits for stable Trypan Blue solutions are provided. In one example, a method includes: cooling a solution of Trypan Blue; and filtering the cooled solution. In another example, a method includes: mixing a water-soluble polymer with a Trypan Blue solution. The method may further include adding one or more ingredients such as an aqueous buffer, an osmolyte, an acid, a base, a buffer, a cell culture medium, water, or combinations thereof.

A method of quantifying a concentration of a chemical entity in a matrix includes combining an aqueous buffer; a reporter reagent including at least one reporter molecule selectively bindable to the chemical entity; an organic, non-polar extraction solvent including an internal standard entity; a wash buffer; and the matrix to thereby prepare a liquid precursor. The method includes solvent extracting a sample from the liquid precursor. The sample includes at least one of the internal standard entity and a plurality of complexes formed from the chemical entity and the at least one reporter molecule. The method also includes scanning the sample with a surface-enhanced Raman spectrometer to produce a dataset including at least one of a plurality of target spectra of the chemical entity and a plurality of reference spectra of the internal standard entity. The method includes processing the dataset to thereby quantify the concentration of the chemical entity.

The invention belongs to the technical field of natural product extraction, separation and purification, and discloses a purification process for green solvent-assisted extraction of eucalyptus oil and a quality control method. The technology is characterized in that a ternary reaction system composed of a natural deep eutectic solvent, a water-phase buffer system and an immobilized biocatalyst is constructed, purification and function enhancement are synchronously achieved through selective bioconversion of unstable components such as alpha-pinene and limonene, and GC-MS and near infrared spectrum are combined for online monitoring and dynamic feedback regulation. According to the process, the chemical stability and safety of the eucalyptus oil are remarkably improved, new functional attributes are given to the product by precisely regulating and controlling a conversion path, and meanwhile, the batch consistency and process controllability of industrial production are ensured through a matched multi-dimensional quality control method; and a complete technical solution is provided for high-valued and green manufacturing of natural essential oil.

The application relates to the technical field of medical carriers, in particular to a cell dispersion carrier and a preparation method and application thereof. The preparation method comprises the following steps: dissolving a hydrophobic peptide segment in an organic solvent, adding nano-magnetic particles containing a magnetic metal organic framework to perform microwave and ultrasonic synergistic dispersion, and obtaining a composite of the magnetic particles and the hydrophobic peptide segment; in a stable magnetic field, the composite is subjected to magnetic separation to obtain a magnetic separation product; the magnetic separation product is dispersed in an aqueous buffer to obtain a magnetic dispersion liquid; the self-assembled short peptide is dissolved in the magnetic dispersion liquid to perform ultrasonic induction to obtain the cell dispersion carrier. The preparation method is connected through four steps of microwave+ultrasonic synergistic dispersion, anchoring of the hydrophobic peptide segment, magnetic separation in a stable magnetic field and ultrasonic induction self-assembly, and finally, a uniform distribution state is dynamically locked in a gelation process, so that the nano-magnetic MOF particles are uniformly dispersed in the hydrogel matrix from the molecular to the macroscopic full-scale.

Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with en trapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Usable life of a biosensor life is extended while keeping the sensing system enclosed and minimizing the introduction of flushing solutions into a measurement line (e.g., a blood vessel) of a fluid system, such as a human blood vessel, a nutritional fluid line in a tissue cultivation system, or a circulation system in an organ preservation system. A catheter, tube, or other lumen contains the active biosensor. One end of the lumen is introduced to the target fluid, and the other end is connected to a supply of a buffer solution (e.g., heparinized saline solution). By advancing the buffer solution along the lumen, the biological fluid (e.g., blood) can be purged from the area around the sensor material to halt any reactions. When a measurement is desired, then the buffer solution is withdrawn (e.g., suctioned) back into the supply so that the biological fluid enters and contacts the sensor material.

This invention relates to a culture medium suitable for cell culture and a process for preparing the same. The culture medium can essentially be prepared by dissolving or mixing individual medium components in water or a suitable aqueous buffer. A key step in the preparation of the medium is a sterilization step. The culture medium according to the present invention may contain protein hydrolysates as an amino acid source. A favorable process for protein hydrolysis to shorter peptide chains and / or single amino acids is also provided by this invention.

An embolic hydrogel for use with a patient comprise an aqueous buffer and at least one functionalized polymer respectively having at least one polymer backbone chemically modified with one or more functional groups. The functional group(s) facilitate formation of primary reversible crosslinks on the polymer backbone(s), such that the embolic hydrogel transitions from a gel state to a viscous liquid state in response to a shear force applied to the embolic hydrogel, and transitions from the viscous liquid state back to the gel state in response to an absence of a shear force applied to the embolic hydrogel. The embolic hydrogel further comprises at least one phase-transitioning polymer that creates secondary crosslinks therein in response to a physiological environment, such that the embolic hydrogel transitions from the gel state to a solid state.